With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
NEW YORK (Reuters Health) – Almost a quarter of overweight women and nearly a half of overweight men in the US think there’s nothing wrong with their weight.…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
NEW YORK (Reuters Health) – Benign or malignant breast lesions can be differentiated noninvasively by overlaying 3-D digital mammography images with tissue-physiology images obtained by scanning with near…
NEW YORK (Reuters Health) – Pregnancy outcomes are improved for overweight women when they adopt a low-glycemic load diet compared with a low-fat diet, a Massachusetts-based group reports…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – Women who have undergone laparoscopic surgery for endometrioma have a reduced risk of recurrence when they take low-dose oral contraceptives, a Korean team…
Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment…
Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment…
NEW YORK (Reuters Health) – Among women undergoing resection of endometrial polyps, the prevalence of malignant or premalignant polyps ranges from about 2% to 5%, with the higher…
NEW YORK (Reuters Health) – Postmenopausal women treated for osteoporosis with the selective estrogen receptor modulator lasofoxifene have a reduced risk of coronary heart disease events, researchers report…
